Skip to main content
. 2018 May 26;109(7):2266–2274. doi: 10.1111/cas.13627

Figure 2.

Figure 2

Relationship between tumor‐infiltrating neutrophils (TIN) and benefit from adjuvant chemotherapy (ACT) in patents with stage III and IV disease. Patients with high TIN in the A, training set; C, validation set; and E, combined set. Patients with low TIN in the B, training set; D, validation set; and F, combined set